NEW YORK (TheStreet) -- Shares of CVS Health (CVS) - Get Report  are climbing 1.29% to $93.92 this afternoon as the company prepares to report 2016 second quarter earnings before Tuesday's opening bell.

Analysts surveyed by Thomson Reuters estimate that the company will earn $1.30 per share and generate $44.28 billion in revenue for the period.

In the 2015 second quarter, CVS reported earnings of $1.22 per share on revenue of $37.17 billion.

Early in July, the company announced a quarterly dividend of 42.5 cents per share payable on August 1.

CVS stock is down 15% for the year, however, industry trends could aid the pharmacy benefit manager in the upcoming quarter. The Food and Drug Administration currently has a backlog of 3,000 applications for branded drugs to turn generic, and CVS should be able to expand its margins as these applications are approved.

CVS is a pharmacy company based in Woodsocket, RI.

Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

TheStreet Ratings rated this stock as a "buy" with a ratings score of A-.

The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and good cash flow from operations. TheStreet Ratings feels its strengths outweigh the fact that the company has had lackluster performance in the stock itself.

You can view the full analysis from the report here: CVS

Image placeholder title